AAV Purification, Characterization, and Lyophilization
A purified AAV product is defined not just by its titer but by its purity, its empty-versus-full capsid profile, and its stability across storage. During AAV development, the workflow must link purification strategy, analytical testing, formulation design, and lyophilization optimization to the specific quality risks that limit clinical readiness.
IntroductionRecombinant AAV must be controlled for process-related and product-related impurities. Process-related impurities include residual host-cell protein, DNA, helper-virus DNA, and manufacturing reagents; product-related impurities center on empty and partially filled capsids. On top of purity, the product must remain stable through storage and freeze-thaw, and must meet Safety requirements for sterility, endotoxin, mycoplasma, adventitious agents, and replication-competent AAV. This guide brings those threads together around a single characterization strategy.
Start With Purity
Control Impurities That Raise Immunotoxicity and Genotoxicity Risk
The production cell line and manufacturing process determine the types of impurity that must be controlled. Residual host-cell protein and nucleic acid drive immunotoxicity and genotoxicity risk, so their levels must be measured and reduced to the lowest achievable level.
Impurity 1 · rcAAV
Replication-competent AAV
rcAAV carries rep and cap flanked by ITRs and can replicate in the presence of helper virus, increasing immunotoxicity risk in transduced tissue. rcAAV cannot be separated by purification, so generation must be minimized in culture; triple transfection tends to produce more rcAAV than stable producer systems. Detection uses serial passage on adenovirus-infected HEK293 or HeLa cells followed by analysis of AAV replication intermediates, or targeted qPCR.
Decision: reduce rcAAV to the lowest feasible level and verify with a sensitive, serotype-matched assay.
Impurity 2 · DNA
Encapsulated and helper DNA
DNA other than the intended genome can be non-specifically packaged, including plasmid backbone (via reverse packaging), antibiotic-resistance genes, and helper-virus sequences. Residual packaged helper DNA in drug product should not exceed 0.1% of vg DNA. Amplifying the pTransgene backbone beyond 5 kb with filler DNA can reduce reverse packaging significantly.
Decision: quantify specific nucleic-acid impurities by qPCR and keep them within defined limits.
Impurity 3 · Free DNA/RNA
Host-cell and free nucleic acids
Free DNA from host cells and helper components remains after purification and can associate with the capsid surface. Residual host-cell DNA should be controlled to ≤10 ng per dose with a median fragment size ≤200 bp, and residual plasmid DNA below 100 pg per 10⁹ vg. qPCR/ddPCR against Alu repeats, 18S rRNA, or housekeeping genes quantifies host DNA.
Decision: screen for host- and helper-derived DNA and enforce size and quantity limits.
Impurity 4 · Protein
Residual host-cell and reagent proteins
Only VP1, VP2, and VP3 should theoretically remain in a purified sample, but host proteins (such as galectin-3 binding protein) and process reagents can co-purify and even induce aggregation or reduce transduction. Protein composition is assessed by SDS-PAGE with sensitive staining, 260/280 OD ratio, commercial ELISA kits, or LC-MS.
Decision: measure and control protein impurities against reference material or defined specifications.
Product-Related Impurities
Distinguish Empty, Partial, and Full Capsids
A large fraction of capsids in standard production (often 50–90%) do not contain a genome. Empty capsids are not therapeutically active and can raise immune or dose concerns, while partially filled capsids add further risk. Each analytical method trades throughput against resolution.
Method
Principle
Strengths
Limitations
Analytical ultracentrifugation (SV-AUC)
Separates by sedimentation rate; full ~100–120 S, partial ~80–95 S, empty ~60–70 S.
Gold standard; resolves partial capsids; good reproducibility.
High sample volume (~400–500 µL) and titer; ~7 samples per 6 h; sample not recovered; expensive.
No total capsid count or vg titer; still maturing for AAV.
No current method distinguishes particles carrying a full, functional genome from those carrying similar-sized fragmented or non-functional genomes, so full-capsid concentration should not be equated with genome titer or transducible particles.
Product Stability
Four Dimensions of AAV Stability
Stability spans conformational, colloidal, interfacial, and chemical change. Together they determine whether a vector remains intact, monomeric, surface-stable, and chemically unmodified through processing, storage, and freeze-thaw.
01
Conformational
Denaturation or capsid changes that eject the genome; assessed by DSC, CD, and fluorescence.
02
Colloidal
Aggregation driven by low ionic strength, free DNA, or high concentration; SEC, AF4-MALS, and DLS detect aggregates.
03
Interfacial
Surface adsorption to packaging and injection devices can lose up to 75% of the vector; poloxamer 188 mitigates it.
04
Chemical
Oxidation, deamidation, disulfide exchange, and isomerization; detected by RP-HPLC, HIC, and IEX.
05
Aggregate Analytics
Submicron and subvisible particles via NTA, TRPS, light obscuration, and flow imaging.
06
Release & Storage
Stability data over time and freeze-thaw cycles inform formulation and shelf life.
Safety Considerations
Four Safety Controls for a Purified AAV Product
Safety testing is the final critical quality attribute and is shaped by the route of administration and production system.
MICROBIAL
Sterility and endotoxin
Drug product must pass sterility and endotoxin testing; permitted endotoxin levels depend on the route of administration. Visible-particle and clarity testing also apply to injectable products.
ADVENTITIOUS
Mycoplasma and adventitious viruses
Absence of mycoplasma and adventitious agents must be demonstrated from the primary harvest stage, and production-cell-line contaminants must be addressed throughout the process.
rcAAV
Replication-competent AAV
rcAAV is tested by infectious-center assay (target: 1 rcAAV in 10⁸ vg) or more reliable targeted qPCR, since the traditional cell-culture readout is imprecise and labor-intensive.
IMMUNOGENICITY
Empty capsids and impurities
Empty capsids and residual impurities can amplify immune responses and limit transgene expression, so purity and full/empty ratio are safety-relevant, not just quality-relevant.
Project Support
Creative Biolabs Support
Creative Biolabs provides linked AAV purification and characterization capabilities that can be scoped around the purity, full/empty profile, and safety requirements of your program.
Generate purified vector under a defined process to support characterization and stability.
References
Sources That Inform This Guide
Purification, characterization and lyophilization of adeno-associated virus vectors. Doctoral thesis, reviewed as the source material for AAV purity, empty-capsid, stability, and safety methods.
ICH Q5A(R2). Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin.
European Medicines Agency. Quality, non-clinical and clinical issues relating specifically to recombinant adeno-associated viral vectors. Scientific guideline.
FAQ
Questions Teams Ask About AAV Purification and Characterization
Empty capsids are not therapeutically active and can account for a large fraction of total particles. They may compete for cell binding sites, act as immune decoys or immune stimulants, and complicate dosing. Because they are immunologically similar to full capsids, their ratio to full capsids can influence transduction and safety.
Analytical ultracentrifugation (SV-AUC) is widely regarded as the reference method because it resolves full, partial, and empty capsids with good reproducibility. It is low throughput and sample-intensive, so it is often used orthogonally to validate higher-throughput methods such as AEX or cIEF.
Residual host-cell DNA and plasmid DNA are quantified by qPCR or ddPCR against targets such as Alu repeats, 18S rRNA, or resistance genes. Guidelines typically require host-cell DNA ≤10 ng per dose with a median fragment ≤200 bp, and residual plasmid DNA below 100 pg per 10⁹ vg, with packaged helper DNA ≤0.1% of vg DNA.
rcAAV carries rep and cap flanked by ITRs and can replicate in the presence of helper virus. It is detected by serial passage on helper-virus-infected cells followed by analysis of replication intermediates, or more practically by targeted qPCR. It cannot be removed by purification, so it must be minimized in the production process.
Aggregation can be driven by high capsid concentration, free DNA, low ionic strength below ~150 mM, and chemical or interfacial stress. It is measured by size-exclusion chromatography, AF4 with MALS, dynamic light scattering, and subvisible-particle methods such as NTA, TRPS, light obscuration, and flow imaging microscopy.
Useful inputs include the serotype, production system, current titer and purity, full/empty ratio, formulation, storage conditions, intended route, and regulatory stage. These factors determine which purification, characterization, stability, and safety assays are most appropriate.
Build a Robust AAV Purification and Characterization Plan
Share your serotype, production system, current purity, and storage requirements. Creative Biolabs can help define a purity, empty-capsid, stability, and safety strategy matched to your program.
